Dr. Sartor Discusses Prostate Cancer Drug Combinations

Oliver Sartor, MD
Published: Tuesday, Nov 29, 2011

Oliver Sartor, MD, medical director, Tulane Cancer Center, discusses the many new drugs that have come on the market recently to treat prostate cancer. The many new agents call for a closer look into combination therapies.

These new therapies have multiple mechanisms of actions such as the immunotherapy sipuleucel-T (Provenge), the radiopharmaceutical radium-223 (Alpharadin), hormonal or androgen deprivation therapies such as abiraterone acetate (Zytiga), and chemotherapy agents.

The goal of research is to take these agents from a sequencing scenario and develop combination therapies. The varying mechanisms of actions make each of these agents unique and allows for interesting combinations.

Oliver Sartor, MD, medical director, Tulane Cancer Center, discusses the many new drugs that have come on the market recently to treat prostate cancer. The many new agents call for a closer look into combination therapies.

These new therapies have multiple mechanisms of actions such as the immunotherapy sipuleucel-T (Provenge), the radiopharmaceutical radium-223 (Alpharadin), hormonal or androgen deprivation therapies such as abiraterone acetate (Zytiga), and chemotherapy agents.

The goal of research is to take these agents from a sequencing scenario and develop combination therapies. The varying mechanisms of actions make each of these agents unique and allows for interesting combinations.


View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Clinical Interchange™: Translating Research to Inform Changing Paradigms: Assessment of Emerging Immuno-Oncology Strategies and Combinations across Lung, Head and Neck, and Bladder CancersOct 31, 20182.0
35th Annual Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow® Clinical Vignette SeriesJan 31, 20192.0
Publication Bottom Border
Border Publication
x